279 related articles for article (PubMed ID: 12365003)
21. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
22. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells.
Lin T; Huang X; Gu J; Zhang L; Roth JA; Xiong M; Curley SA; Yu Y; Hunt KK; Fang B
Oncogene; 2002 Nov; 21(52):8020-8. PubMed ID: 12439752
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
24. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Liu J; Fang B
Int J Oncol; 2003 Jun; 22(6):1241-5. PubMed ID: 12738989
[TBL] [Abstract][Full Text] [Related]
25. Enforced expression of a truncated form of Bax-alpha (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Toyota H; Kondo S; Kyo S; Mizuguchi J
Anticancer Res; 2006; 26(1A):99-105. PubMed ID: 16475685
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice.
Shi J; Zheng D; Liu Y; Sham MH; Tam P; Farzaneh F; Xu R
Cancer Res; 2005 Mar; 65(5):1687-92. PubMed ID: 15753363
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation.
Kim M; Park SY; Pai HS; Kim TH; Billiar TR; Seol DW
Cancer Res; 2004 Jun; 64(12):4078-81. PubMed ID: 15205314
[TBL] [Abstract][Full Text] [Related]
28. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
Ma H; Liu Y; Liu S; Xu R; Zheng D
Hepatology; 2005 Dec; 42(6):1355-63. PubMed ID: 16317690
[TBL] [Abstract][Full Text] [Related]
29. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
30. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL.
Burroughs KD; Kayda DB; Sakhuja K; Hudson Y; Jakubczak J; Bristol JA; Ennist D; Hallenbeck P; Kaleko M; Connelly S
Cancer Gene Ther; 2004 Feb; 11(2):92-102. PubMed ID: 14730331
[TBL] [Abstract][Full Text] [Related]
32. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
33. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.
Mohr A; Henderson G; Dudus L; Herr I; Kuerschner T; Debatin KM; Weiher H; Fisher KJ; Zwacka RM
Gene Ther; 2004 Mar; 11(6):534-43. PubMed ID: 14999225
[TBL] [Abstract][Full Text] [Related]
34. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
Lancaster JM; Sayer R; Blanchette C; Calingaert B; Whitaker R; Schildkraut J; Marks J; Berchuck A
Clin Cancer Res; 2003 Feb; 9(2):762-6. PubMed ID: 12576447
[TBL] [Abstract][Full Text] [Related]
35. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
36. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Vanoosten RL; Moore JM; Ludwig AT; Griffith TS
Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.
Li X; Marani M; Yu J; Nan B; Roth JA; Kagawa S; Fang B; Denner L; Marcelli M
Cancer Res; 2001 Jan; 61(1):186-91. PubMed ID: 11196158
[TBL] [Abstract][Full Text] [Related]
38. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kazhdan I; Marciniak RA
Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
[TBL] [Abstract][Full Text] [Related]
39. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
40. [Construction of TRAIL gene eukaryotic expression vector modulated by hTERT gene core promoter and its effect on apoptosis of ovarian cancer cells].
Li HM; Song TB; Yu YC; Cao YX; Wang HY; Song H; Zhang M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar; 22(2):243-6. PubMed ID: 16507264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
